Cannabinoid Encyclopedia

Cannabinoid guide

What is CBDV-A?

A clear guide to CBDV-A: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 13 research sources Mostly early-stage research

The short answer

CBDV-A, in simple terms

CBDV-A is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. Most of the current evidence is preclinical or focused on biological mechanisms. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBDV-A.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBDV-A

What CBDV-A is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Mostly mechanism-focused

    Receptors and pharmacology

    This is part of the biological explanation for why CBDV-A may have effects in cells or models. Mechanism research does not by itself show a health benefit in people. 2

    See research areas

  2. Mostly mechanism-focused

    Receptor, target, metabolic, and pharmacology mechanisms

    Researchers have looked at CBDV-A in appetite or metabolism-related models. That does not show that it changes appetite, weight, or metabolism for people. 3

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on CBDV-A covers Receptors and pharmacology and Receptor, target, metabolic, and pharmacology mechanisms; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has CBDV-A been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Receptors and pharmacology

Researchers have examined CBDV-A in connection with Receptors and pharmacology. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Mostly mechanism-focused

Receptor, target, metabolic, and pharmacology mechanisms

Studies connect CBDV-A with Receptor, target, metabolic, and pharmacology mechanisms at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 3

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

1 source

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

1 source

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

6 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 5 of 13 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBDV-A is not one kind of study. This source set includes 3 animal studies, 3 cell or laboratory studies, and 1 narrative or expert review. 3

The recorded populations or models include animal models (2 sources), cells or tissue models (2 sources), and pediatric, adolescent, or developmental context (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is receptor, target, or pharmacology mechanisms (12 sources) and receptor, target, metabolic, or pharmacology mechanisms (1 source). Closely related outcome names can still describe different measurements. 5

The CBDV-A source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Pharmacokinetics of Non-Psychotropic Phytocannabinoids.

On this page, this source examines CBD and receptor, target, or pharmacology mechanisms. 1

Study type
narrative or expert review
Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
evidence still limited

evidence still limited

Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids.

On this page, this source examines THC and receptor, target, or pharmacology mechanisms. 2

Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
evidence still limited

mechanism-focused research

An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.

On this page, this source examines THCV activity involving receptor, target, metabolic, or pharmacology mechanisms. 3

Outcome focus
receptor, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

animal study

Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain.

On this page, this source examines THC and receptor, target, or pharmacology mechanisms. 4

Study type
animal study
Population or model
animal models
Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
mechanism-focused research

animal study

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.

On this page, this source examines CBD and receptor, target, or pharmacology mechanisms. 5

Study type
animal study
Population or model
pediatric, adolescent, or developmental context
Outcome focus
receptor, target, or pharmacology mechanisms
Evidence stage
preclinical research

Safety and limits

What should readers keep in mind?

Research on CBDV-A should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBDV-A?

CBDV-A is a cannabinoid-related compound studied across Receptors and pharmacology and Receptor, target, metabolic, and pharmacology mechanisms. This page separates those research questions so they are not mistaken for one broad claim. 7

What has CBDV-A been studied for?

The current source set includes Receptors and pharmacology and Receptor, target, metabolic, and pharmacology mechanisms. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on CBDV-A?

Most of the current evidence is preclinical or focused on biological mechanisms. 9

Is CBDV-A safe?

Safety cannot be answered for CBDV-A without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited PubMed 40006604 DOI 10.3390/pharmaceutics17020236
  2. 2
    Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. evidence still limited PubMed 36257598 DOI 10.1055/a-1962-8165
  3. 3
    An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. mechanism-focused research PubMed 34500785 DOI 10.3390/molecules26175352
  4. 4
    Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. animal study; mechanism-focused research PubMed 38162115 DOI 10.1093/function/zqad069
  5. 5
    Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. animal study; preclinical research PubMed 34384142 DOI 10.1111/bph.15661
  6. 6
    Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. animal study; mechanism-focused research PubMed 34980287 DOI 10.1186/s42238-021-00113-w
  7. 7
    Antiviral activities of hemp cannabinoids. cell or laboratory study; mechanism-focused research PubMed 37083031 DOI 10.1042/cs20220193
  8. 8
    Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. evidence still limited PubMed 37708768 DOI 10.1016/j.talanta.2023.125161
  9. 9
    Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'. evidence still limited PubMed 39013926 DOI 10.1038/s41598-024-66420-3
  10. 10
    Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. evidence still limited PubMed 35566314 DOI 10.3390/molecules27092965
  11. 11
    Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. evidence still limited PubMed 39808700 DOI 10.1021/acssynbio.4c00721
  12. 12
    In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; evidence still limited PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
See all 13 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Development and Validation of a GC-FID Method for the Quantitation of 20 Different Acidic and Neutral Cannabinoids. evidence still limited / 1 linked research note PubMed 36257598
  2. Antiviral activities of hemp cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37083031
  3. Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. animal study; mechanism-focused research / 1 linked research note PubMed 38162115
  4. Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. animal study; mechanism-focused research / 1 linked research note PubMed 34980287
  5. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. animal study; preclinical research / 1 linked research note PubMed 34384142
  6. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 40006604
  7. Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. cell or laboratory study; evidence still limited / 1 linked research note PubMed 32824356
  8. Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. evidence still limited / 1 linked research note PubMed 39808700
  9. In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; evidence still limited / 1 linked research note PubMed 35306000
  10. Bidimensional heart-cut achiral-chiral liquid chromatography coupled to high-resolution mass spectrometry for the separation of the main chiral phytocannabinoids and enantiomerization studies of cannabichromene and cannabichromenic acid. evidence still limited / 1 linked research note PubMed 37708768
  11. Comparison of decarboxylation rates of acidic cannabinoids between secretory cavity contents and air-dried inflorescence extracts in Cannabis sativa cv. 'Cherry Wine'. evidence still limited / 1 linked research note PubMed 39013926
  12. Direct Quantitation of Phytocannabinoids by One-Dimensional 1H qNMR and Two-Dimensional 1H-1H COSY qNMR in Complex Natural Mixtures. evidence still limited / 1 linked research note PubMed 35566314
  13. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. mechanism-focused research / 1 linked research note PubMed 34500785